Steven Pfanstiel's most recent trade in Neuronetics Inc was a trade of 16,431 Common Stock done at an average price of $1.3 . Disclosure was reported to the exchange on March 19, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neuronetics Inc | Steven Pfanstiel | EVP, CFO and Treasurer | Sale of securities on an exchange or to another person at price $ 1.34 per share. | 19 Mar 2026 | 16,431 | 828,781 (4%) | 0% | 1.3 | 22,018 | Common Stock |
| Neuronetics Inc | Steven Pfanstiel | Former EVP, CFO and Treasurer | Sale of securities on an exchange or to another person at price $ 1.34 per share. | 19 Mar 2026 | 8,569 | 836,643 (4%) | 0% | 1.3 | 11,482 | Common Stock |
| Neuronetics Inc | Steven Pfanstiel | EVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2026 | 25,000 | 845,212 (4%) | 0% | 0 | Common Stock | |
| Neuronetics Inc | Steven Pfanstiel | EVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2026 | 250,000 | 820,212 (4%) | 1% | 0 | Common Stock | |
| Neuronetics Inc | Steven Pfanstiel | EVP, CFO and Treasurer | 30 Dec 2025 | 170,212 | 570,212 (3%) | 0% | 0 | Common Stock | ||
| Neuronetics Inc | Steven Pfanstiel | EVP, CFO and Treasurer | 15 Jul 2025 | 200,000 | 400,000 (2%) | 1% | 0 | Common Stock | ||
| Neuronetics Inc | Steven Pfanstiel | EVP, CFO and Treasurer | 15 Jul 2025 | 200,000 | 200,000 (1%) | 1% | 0 | Common Stock | ||
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CFO AND COO | Sale of securities on an exchange or to another person at price $ 1.13 per share. | 05 Aug 2024 | 4,657 | 79,773 (0%) | 0% | 1.1 | 5,262 | Common Stock |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CFO AND COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 57,300 | 57,300 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CFO AND COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 12,733 | 84,430 (0%) | 0% | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CFO AND COO | Sale of securities on an exchange or to another person at price $ 9.97 per share. | 16 Feb 2024 | 3,092 | 71,697 (0%) | 0% | 10.0 | 30,827 | Common Stock |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CFO AND COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 114,600 | 114,600 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Pfanstiel Steven | CFO AND COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 25,465 | 74,789 (0%) | 0% | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CFO AND COO | Sale of securities on an exchange or to another person at price $ 9.54 per share. | 07 Aug 2023 | 2,790 | 49,338 (0%) | 0% | 9.5 | 26,617 | Common Stock |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CFO AND COO | Sale of securities on an exchange or to another person at price $ 8.93 per share. | 07 Aug 2023 | 14 | 49,324 (0%) | 0% | 8.9 | 125 | Common Stock |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 126,585 | 126,585 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 28,130 | 52,128 (0%) | 0% | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 7,448 | 23,998 (0%) | 0% | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 74,475 | 74,475 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Steven Pfanstiel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 16,550 | 16,550 (0%) | 0% | 0 | Common Stock |